Intravitreal complement inhibitor injections (IVCIs) for geographic atrophy appeared to be acceptable to most patients if they assumed the treatment had functional vision benefits, a cross-sectional ...
WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and DERBY studies ...
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpoint Data presented at the Clinical Trials at the Summit Meeting In a prespecified ...
WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of ...
Concurrent exudative disease, early intervention, and a rare masquerader complicate the classic picture of geographic atrophy ...
A Media Snippet accompanying this announcement is available by clicking on the image or link below: WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In 2024, Healio covered several stories about trials ...
No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis Confirmed seven total events of non-occlusive/occlusive retinal vasculitis since launch; more ...
Sheppard, MD: There have been remarkable changes, with two new injections to arrest or delay the inevitable blinding progression of geographic atrophy. When patients and referring doctors better ...
A mixed-logit analysis showed lesion growth rate reduction drove choice (40.9%-52.1% RAI), especially for foveal-threatening lesions and poor visual acuity in the unaffected eye. Conversion to wet AMD ...
A novel outcome measure for geographic atrophy, the Geographic Atrophy Weighted-by-Acuity Index, aligned with best-corrected visual acuity, showing better correlation and predictive accuracy than the ...
Randomized trials of two FDA-approved intravitreal complement inhibitor injections showed that they slowed the progression of geographic atrophy, but failed to demonstrate functional benefits at 24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results